Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + polatuzumab vedotin + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Pola-R-CHP is a combination chemotherapy regimen used as a first-line treatment for patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL). It consists of the antibody-drug conjugate polatuzumab vedotin, the anti-CD20 monoclonal antibody rituximab, and the chemotherapy agents cyclophosphamide, doxorubicin, and prednisone. Polatuzumab vedotin targets CD79b, a protein expressed on B-cells, and delivers the cytotoxic payload monomethyl auristatin E (MMAE), which inhibits microtubule polymerization. Rituximab targets CD20 to induce B-cell lysis. The regimen was established as a standard of care following the Phase III POLARIX trial, which demonstrated improved progression-free survival compared to the traditional R-CHOP regimen by replacing vincristine with polatuzumab vedotin.
- Other names
- Pola-R-CHPpolatuzumab vedotin plus R-CHPpolatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + polatuzumab vedotin + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + polatuzumab vedotin + cyclophosphamide + doxorubicin + prednisone.